Aquestive Therapeutics is trading 5.59% up now at $4.53 after positive Anaphylm human-factors and pharmacokinetic results supported a planned third-quarter 2026 FDA resubmission.

  • Revised packaging reduced median pouch-opening time from 17 seconds to 3 seconds.
  • Self-administration pharmacokinetics were comparable with clinician administration.
  • Second-quarter results are scheduled after market close on August 11, 2026.